Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kimberly Weaver

Nurse Practitioner, Primary Care Hickory, NC Nurse Practitioner

NPI 1841653359 CMS profile 10581249

2874 Nc Hwy 127 South, Hickory, NC 28602

Open in the dashboard

General payments

$8,750

539 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kimberly Weaver of Hickory, NC is reported in the CMS Open Payments database as having received $8,750 across 539 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,685 95
2024 General $1,586 93
2023 General $2,188 129
2022 General $1,652 105
2021 General $1,639 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kimberly Weaver
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Kimberly Weaver were reported at $1,685. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Kimberly Weaver Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,639 $137 $39–$445 $132
2022 $1,652 $139 $44–$421 $149
2023 $2,188 $163 $53–$481 $160
2024 $1,586 $176 $54–$511 $164
2025 $1,685 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,469 118 payments
  2. Novo Nordisk Inc $1,143 74 payments
  3. AstraZeneca Pharmaceuticals LP $706 40 payments
  4. Lilly USA, LLC $680 40 payments
  5. Pfizer Inc. $557 30 payments
  6. GlaxoSmithKline, LLC. $321 17 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $313 19 payments
  8. Dexcom, Inc. $286 12 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $255 14 payments
  10. Amgen Inc. $205 12 payments
  11. Other $2,814 163 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,750 539 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $865 64 payments
  2. RYBELSUS $661 42 payments
  3. Ozempic $654 42 payments
  4. MOUNJARO $407 22 payments
  5. VRAYLAR $364 35 payments
  6. NURTEC ODT $324 18 payments
  7. Dexcom G6 Transmitter $286 12 payments
  8. FARXIGA $286 17 payments
  9. QULIPTA $266 22 payments
  10. BREZTRI $260 15 payments
  11. Other $7,004 405 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

3,222

Median for Nurse Practitioner: 389

Drug cost

$230,616

Median for Nurse Practitioner: $21,885

Branded share of claims

21.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 39 $54,056
Mounjaro Tirzepatide Brand 34 $34,395
Jardiance Empagliflozin Brand 29 $24,736
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 24 $23,799
Eliquis Apixaban Brand 25 $19,481
Rybelsus Semaglutide Brand 11 $18,925
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 18 $17,830
Synthroid Levothyroxine Sodium Brand 47 $2,851
Celecoxib Generic 22 $2,688
Lantus Insulin Glargine,hum.Rec.Anlog Brand 11 $2,041

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$25,524

Of which drugs: $12,941

Medicare patients

83

Average age 72

Services billed

801

64 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 43%
Diabetes 41%
Depression 25%
COPD 23%
Chronic kidney disease 22%
Osteoporosis 22%
Ischemic heart disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 16 16 $1,309

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$145 — —
Auvelity
$82 — —
JARDIANCE
$80 29 —
AIRSUPRA
$78 — —
MOUNJARO
$59 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

539 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record